These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

565 related items for PubMed ID: 15894116

  • 1. Specific antitumor immune response induced by a novel DNA vaccine composed of multiple CTL and T helper cell epitopes of prostate cancer associated antigens.
    Qin H, Zhou C, Wang D, Ma W, Liang X, Lin C, Zhang Y, Zhang S.
    Immunol Lett; 2005 Jun 15; 99(1):85-93. PubMed ID: 15894116
    [Abstract] [Full Text] [Related]

  • 2. Enhancement of antitumour immunity by a novel chemotactic antigen DNA vaccine encoding chemokines and multiepitopes of prostate-tumour-associated antigens.
    Qin H, Zhou C, Wang D, Ma W, Liang X, Lin C, Zhang Y, Zhang S.
    Immunology; 2006 Mar 15; 117(3):419-30. PubMed ID: 16476062
    [Abstract] [Full Text] [Related]

  • 3. Vaccination with recombinant adenoviruses and dendritic cells expressing prostate-specific antigens is effective in eliciting CTL and suppresses tumor growth in the experimental prostate cancer.
    Kim S, Lee JB, Lee GK, Chang J.
    Prostate; 2009 Jun 15; 69(9):938-48. PubMed ID: 19267351
    [Abstract] [Full Text] [Related]

  • 4. Potent systemic antitumor immunity induced by vaccination with chemotactic-prostate tumor associated antigen gene-modified tumor cell and blockade of B7-H1.
    Li N, Qin H, Li X, Zhou C, Wang D, Ma W, Lin C, Zhang Y, Wang S, Zhang S.
    J Clin Immunol; 2007 Jan 15; 27(1):117-30. PubMed ID: 17180470
    [Abstract] [Full Text] [Related]

  • 5. Human CTL epitopes prostatic acid phosphatase-3 and six-transmembrane epithelial antigen of prostate-3 as candidates for prostate cancer immunotherapy.
    Machlenkin A, Paz A, Bar Haim E, Goldberger O, Finkel E, Tirosh B, Volovitz I, Vadai E, Lugassy G, Cytron S, Lemonnier F, Tzehoval E, Eisenbach L.
    Cancer Res; 2005 Jul 15; 65(14):6435-42. PubMed ID: 16024648
    [Abstract] [Full Text] [Related]

  • 6. Vaccination with a DNA vaccine based on human PSCA and HSP70 adjuvant enhances the antigen-specific CD8+ T-cell response and inhibits the PSCA+ tumors growth in mice.
    Zhang X, Yu C, Zhao J, Fu L, Yi S, Liu S, Yu T, Chen W.
    J Gene Med; 2007 Aug 15; 9(8):715-26. PubMed ID: 17595048
    [Abstract] [Full Text] [Related]

  • 7. Identification of T helper epitopes from prostatic acid phosphatase.
    McNeel DG, Nguyen LD, Disis ML.
    Cancer Res; 2001 Jul 01; 61(13):5161-7. PubMed ID: 11431355
    [Abstract] [Full Text] [Related]

  • 8. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.
    Karan D, Dubey S, Van Veldhuizen P, Holzbeierlein JM, Tawfik O, Thrasher JB.
    Immunotherapy; 2011 Jun 01; 3(6):735-46. PubMed ID: 21668311
    [Abstract] [Full Text] [Related]

  • 9. Synergistic antitumor effect of chemotactic-prostate tumor-associated antigen gene-modified tumor cell vaccine and anti-CTLA-4 mAb in murine tumor model.
    Li N, Qin H, Li X, Zhou C, Wang D, Ma W, Lin C, Zhang Y, Wang S, Zhang S.
    Immunol Lett; 2007 Nov 15; 113(2):90-8. PubMed ID: 17913245
    [Abstract] [Full Text] [Related]

  • 10. Utilization of MHC class I transgenic mice for development of minigene DNA vaccines encoding multiple HLA-restricted CTL epitopes.
    Ishioka GY, Fikes J, Hermanson G, Livingston B, Crimi C, Qin M, del Guercio MF, Oseroff C, Dahlberg C, Alexander J, Chesnut RW, Sette A.
    J Immunol; 1999 Apr 01; 162(7):3915-25. PubMed ID: 10201910
    [Abstract] [Full Text] [Related]

  • 11. Molecular and immunological analysis of genetic prostate specific antigen (PSA) vaccine.
    Kim JJ, Trivedi NN, Wilson DM, Mahalingam S, Morrison L, Tsai A, Chattergoon MA, Dang K, Patel M, Ahn L, Boyer JD, Chalian AA, Schoemaker H, Kieber-Emmons T, Agadjanyan MA, Weiner DB.
    Oncogene; 1998 Dec 17; 17(24):3125-35. PubMed ID: 9872328
    [Abstract] [Full Text] [Related]

  • 12. [Immunotherapeutic efficacy of both helper T lymphocytes and cytotoxic T lymphocytes epitopes augmented dendritic cells tumor vaccine on gastric cancer].
    Li Q, Zhang Y, Chen XH, Cao WX, Gu QL, Zhu ZG, Liu BY.
    Zhonghua Wei Chang Wai Ke Za Zhi; 2006 Mar 17; 9(2):148-51. PubMed ID: 16555158
    [Abstract] [Full Text] [Related]

  • 13. Recognition of prostate and melanoma tumor cells by six-transmembrane epithelial antigen of prostate-specific helper T lymphocytes in a human leukocyte antigen class II-restricted manner.
    Kobayashi H, Nagato T, Sato K, Aoki N, Kimura S, Murakami M, Iizuka H, Azumi M, Kakizaki H, Tateno M, Celis E.
    Cancer Res; 2007 Jun 01; 67(11):5498-504. PubMed ID: 17545632
    [Abstract] [Full Text] [Related]

  • 14. Deoxyribonucleic acid (DNA) encoding a pan-major histocompatibility complex class II peptide analogue augmented antigen-specific cellular immunity and suppressive effects on tumor growth elicited by DNA vaccine immunotherapy.
    Teramoto K, Kontani K, Ozaki Y, Sawai S, Tezuka N, Nagata T, Fujino S, Itoh Y, Taguchi O, Koide Y, Asai T, Ohkubo I, Ogasawara K.
    Cancer Res; 2003 Nov 15; 63(22):7920-5. PubMed ID: 14633722
    [Abstract] [Full Text] [Related]

  • 15. In vivo effects of vaccination with six-transmembrane epithelial antigen of the prostate: a candidate antigen for treating prostate cancer.
    Garcia-Hernandez Mde L, Gray A, Hubby B, Kast WM.
    Cancer Res; 2007 Feb 01; 67(3):1344-51. PubMed ID: 17283172
    [Abstract] [Full Text] [Related]

  • 16. Prostate stem cell antigen vaccination induces a long-term protective immune response against prostate cancer in the absence of autoimmunity.
    Garcia-Hernandez Mde L, Gray A, Hubby B, Klinger OJ, Kast WM.
    Cancer Res; 2008 Feb 01; 68(3):861-9. PubMed ID: 18245488
    [Abstract] [Full Text] [Related]

  • 17. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control.
    Sorensen MR, Holst PJ, Pircher H, Christensen JP, Thomsen AR.
    Eur J Immunol; 2009 Oct 01; 39(10):2725-36. PubMed ID: 19637230
    [Abstract] [Full Text] [Related]

  • 18. [Novel vaccines against M. tuberculosis].
    Okada M.
    Kekkaku; 2006 Dec 01; 81(12):745-51. PubMed ID: 17240920
    [Abstract] [Full Text] [Related]

  • 19. Tumor-reactive T helper lymphocytes recognize a promiscuous MAGE-A3 epitope presented by various major histocompatibility complex class II alleles.
    Kobayashi H, Song Y, Hoon DS, Appella E, Celis E.
    Cancer Res; 2001 Jun 15; 61(12):4773-8. PubMed ID: 11406551
    [Abstract] [Full Text] [Related]

  • 20. Identification and characterization of a WT1 (Wilms Tumor Gene) protein-derived HLA-DRB1*0405-restricted 16-mer helper peptide that promotes the induction and activation of WT1-specific cytotoxic T lymphocytes.
    Fujiki F, Oka Y, Tsuboi A, Kawakami M, Kawakatsu M, Nakajima H, Elisseeva OA, Harada Y, Ito K, Li Z, Tatsumi N, Sakaguchi N, Fujioka T, Masuda T, Yasukawa M, Udaka K, Kawase I, Oji Y, Sugiyama H.
    J Immunother; 2007 Apr 15; 30(3):282-93. PubMed ID: 17414319
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.